A group of cancer genetics researchers in Italy and the U.S. has retracted three papers in the Journal of Biological Chemistry (JBC) after it became aware they had duplicated some bands in their figures.
Here are the three papers: Continue reading Cancer genetics group retracts three papers for “inappropriate presentation of data”
Two researchers at the University of Maryland who retracted a paper earlier this year for a duplicated figure have withdrawn another, this time for unknown reasons.
The Journal of Biological Chemistry (JBC) paper has been cited 16 times, according to Thomson Scientific’s Web of Knowledge.
Here’s the notice, for “Hsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation,” which is unfortunately a return to the JBC’s opacity: Continue reading University of Maryland researchers notch second retraction
The Journal of Biological Chemistry has an illuminating retraction notice — we’re happy to be able to say — about a 2001 article from a group of researchers at the National University of Singapore.
The paper, “Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells,” was written by Jayshree L. Hirpara, Marie-Véronique Clément and Shazib Pervaiz.
It has has been cited 110 times, according to Thomson Scientific’s Web of Knowledge. According to the retraction notice: Continue reading Data highjinx forces retraction of tumor paper in JBC
Shigeaki Kato, the former University of Tokyo endocrinology researcher who resigned in 2012 and has retracted at least ten papers, by our count, has five more retractions.
Here are the papers, all in the Journal of Biological Chemistry (JBC): Continue reading Five more retractions appear for Shigeaki Kato
Two cancer researchers who hold a patent on a particular pathway that might be a target for new drugs — and one of whom leads a company that is studying those potential drugs — have retracted two related papers in the Journal of Biological Chemistry (JBC).
The notices for “Kinase suppressor of Ras signals through Thr269 of c-Raf-1” and “The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK,” which share H. Rosie Xing and Memorial Sloan-Kettering’s Richard Kolesnick as authors, say the same thing: Continue reading Cancer researchers retract two papers in the JBC
A group of authors from Emory University, has lost another paper for image manipulation, bringing their total to at least four. What makes this particularly interesting is that the main actor in the figure fakery, Lian Zuo, does not appear to have been involved this time.
Zuo, you may recall, was cited in multiple retraction notices back in 2011 after Emory investigators concluded that he appeared to have been fabricating figures. But, one of the notices, from Circulation Research, raised the possibility that someone else was implicated, too: Continue reading Another image falsification retraction for Emory heart researchers
The Journal of Biological Chemistry has a fairly gory correction — we’d call it a mega-correction — for a 2010 paper by Levon Khachigian, an Australian researcher whose studies of a new drug for skin cancer recently were halted over concerns about possible misconduct, including image manipulation. As we reported earlier this year, Khachigian has already lost four papers, including one in the JBC — which the journal simply noted had “been withdrawn by the authors.”
The new correction involves the article “c-Jun regulates shear- and injury-inducible Egr-1 expression, vein graft stenosis after autologous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins,” which Khachigian wrote with Jun Ni and Alla Waldman. The paper has been cited nine times, according to Thomson Scientific’s Web of Knowledge. Here’s the notice: Continue reading JBC issues correction for paper by Khachigian, who has had four others retracted
Rakesh Kumar, a professor at the George Washington University, has retracted a paper in the Journal of Biological Chemistry (JBC) that was recently questioned on PubPeer.
Here are Peer1’s comments from PubPeer about the paper, “Mechanism of MTA1 Protein Overexpression-linked Invasion:” Continue reading Author with six recent corrections retracts JBC paper questioned on PubPeer
An assistant professor of neuroscience at Tufts has withdrawn a paper published last year after one round of corrections wasn’t enough to fix all of the study’s problems.
The study, “Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein,” by Gizem Donmez and colleagues, had already been subject to an extensive correction in May: Continue reading Authors withdraw already-corrected JBC paper questioned on PubPeer
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).